Tag: get high
-
Harborside (HBOR.C) books 2020 revenues of $63 million – 130% of its market cap
Harborside’s full year 2020 gross revenues expanded 29% year-over-year to $63.4 million.
-
Xphyto (XPHY.C) bulks up executive team as Covid-19 ravages Europe
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.
-
![Harborside (HBOR.C) invests $5-million in Loudpack – a CA cultivator with a deep portfolio of branded products]()
Harborside (HBOR.C) invests $5-million in Loudpack – a CA cultivator with a deep portfolio of branded products
Loudpack is a California cannabis company with “a broad cultivation, manufacturing, processing, and distribution footprint and a strong portfolio of brands”.
-
That was quick! Xphyto (XPHY.C) orders 9,600 Covid-19 PCR tests – stock up 67% year-to-date
“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting viral RNA, which will be present in the body before symptoms of the disease are present,” the tests give a powerful early warning system.
-
![Xphyto (XPHY.C) assembles biotech/biz dream-team to launch 25-minute Covid-19 test]()
Xphyto (XPHY.C) assembles biotech/biz dream-team to launch 25-minute Covid-19 test
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.
-
![Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine]()
Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”.
-
![Harborside (HBOR.C) raises $20 million, narrows focus on California, projects 2021 cannabis revenues equal to its current market cap]()
Harborside (HBOR.C) raises $20 million, narrows focus on California, projects 2021 cannabis revenues equal to its current market cap
The January 20, 2021 press release declared that HBOR is “expecting gross revenues in line with previously issued guidance of approximately $61 – 63 million, and positive EBITDA”.
-
![Delic (DELC.C) adds Hollywood legend to psychedelic advisory board]()
Delic (DELC.C) adds Hollywood legend to psychedelic advisory board
The company’s platform includes “The Delic”, an e-commerce lifestyle brand, “Reality Sandwich”, a free public education platform and “Meet Delic” – a psychedelic wellness summit with its first planned event on May 1, 2021 in Los Angeles.
-
![Harborside (HBOR.C) buys another California dispensary]()
Harborside (HBOR.C) buys another California dispensary
With HBOR’s track record of revenue-growth-per-location, the addition of FGW is likely to accelerate revenue growth.
-
![Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver]()
Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver
On Thursday, December 17th, 2020 the Virtual Life Sciences Investor Forum (VLSIF) presents a six biotech companies.
